| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124391 | European Journal of Cancer | 2009 | 10 Pages |
Abstract
Health economics have unfortunately limited the universal use of bevacizumab, but it is hoped that the future identification of predictive biomarkers may enhance the benefits and thereby improve cost-effectiveness.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alicia Okines, David Cunningham,